Cerulean Pharma Company Profile (NASDAQ:CERU)

Analyst Ratings

Consensus Ratings for Cerulean Pharma (NASDAQ:CERU) (?)
Ratings Breakdown: 8 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.00 (264.96% upside)

Analysts' Ratings History for Cerulean Pharma (NASDAQ:CERU)
Show:
DateFirmActionRatingPrice TargetActions
6/26/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016Janney Montgomery ScottInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/3/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/19/2016WedbushReiterated RatingOutperform$9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JPMorgan Chase & Co.Boost Price TargetMarket Outperform$9.00 -> $16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$16.00 -> $9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/24/2016Barclays PLCLower Price TargetOverweight$8.00 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/2/2016Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Cerulean Pharma (NASDAQ:CERU)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/2/2016Q116($0.43)($0.49)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q415($0.41)($0.39)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/16/2015Q315($0.41)($0.39)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.43)($0.37)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/19/2015($0.36)($0.37)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014($0.32)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014($0.36)($0.34)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/29/2014($3.52)($3.70)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cerulean Pharma (NASDAQ:CERU)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.42)($0.38)($0.40)
Q2 20162($0.49)($0.48)($0.49)
Q3 20162($0.50)($0.37)($0.44)
Q4 20162($0.52)($0.38)($0.45)
Q1 20171($0.39)($0.39)($0.39)
Q2 20171($0.39)($0.39)($0.39)
Q3 20171($0.40)($0.40)($0.40)
Q4 20171($0.33)($0.33)($0.33)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cerulean Pharma (NASDAQ:CERU)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cerulean Pharma (NASDAQ:CERU)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
2/22/2016David R WaltDirectorBuy2,291$2.08$4,765.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2016David R. WaltDirectorBuy8,960$2.10$18,816.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/16/2016David R. WaltDirectorBuy8,811$2.00$17,622.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/11/2016David R. WaltDirectorBuy8,850$2.05$18,142.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/9/2016David R. WaltDirectorBuy9,000$2.15$19,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2016David R. WaltDirectorBuy8,563$2.30$19,694.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2016David R. WaltDirectorBuy8,413$2.32$19,518.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2016David R. WaltDirectorBuy5,700$2.38$13,566.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/28/2016David R. WaltDirectorBuy9,000$2.46$22,140.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/26/2016David R. WaltDirectorBuy8,800$2.39$21,032.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/25/2016David R. WaltDirectorBuy4,500$2.35$10,575.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/22/2016David R. WaltDirectorBuy9,000$2.28$20,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2016David R. WaltDirectorBuy8,900$2.43$21,627.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2016David R. WaltDirectorBuy8,572$2.53$21,687.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/13/2016David R. WaltDirectorBuy8,684$2.79$24,228.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/11/2016David R. WaltDirectorBuy8,855$2.87$25,413.85View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2016David R. WaltDirectorBuy8,800$2.95$25,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2016David R. WaltDirectorBuy8,801$3.03$26,667.03View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/30/2015David R WaltDirectorBuy5,374$3.25$17,465.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/27/2015David R. WaltDirectorBuy12,117$3.32$40,228.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2015Cvf, LlcMajor ShareholderBuy333,333$6.00$1,999,998.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2014Alan L CraneDirectorBuy1,470,582$7.00$10,294,074.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2014Eli & Co LillyMajor ShareholderBuy733,445$7.00$5,134,115.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2014Lux Capital Management, LlcInsiderBuy106,224$7.00$743,568.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cerulean Pharma (NASDAQ:CERU)
DateHeadline
07/23/16 07:25 AMBiotech Decliners: Heat Biologics, Inc. (NASDAQ:HTBX), Zafgen, Inc. (NASDAQ:ZFGN), Cerulean Pharma Inc ... - KC Register
07/23/16 07:25 AMIncreased Volatility Noted on Shares of: Cerulean Pharma Inc. (NASDAQ:CERU) - Engelwood Daily
07/23/16 07:25 AMEquity Roundup: Stock Performance Focus on Cerulean Pharma Inc. (NASDAQ:CERU) - Press Telegraph
07/23/16 07:25 AMDoes Cerulean Pharma Inc Have Any Gas After Today's Huge Decline? - Consumer Eagle
07/22/16 03:10 PMStocks Buzz: Blackhawk Network (HAWK), Noble Energy (NBL) Cerulean Pharma (CERU) - iStreetWire
07/22/16 03:10 PMWhat Next for Cerulean Pharma Inc Stock After Today's Huge Decline? - Consumer Eagle
07/21/16 08:42 PMRNC Latest: Look for a compassionate, human Trump
07/21/16 03:13 PMStocks Buzz: Noble Energy, Inc. (NBL) Cerulean Pharma Inc. (CERU) Blackhawk Network Holdings, Inc. (HAWK) - iStreetWire
07/21/16 03:13 PMShares Losing Ground in Trade: Cerulean Pharma Inc. (NASDAQ:CERU) - TGP
07/21/16 03:13 PMAnalysts Observing Stocks Update: Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) , Cerulean Pharma Inc ... - Street Updates
07/21/16 03:13 PMNews review of 2 biotech stocks: Cerulean Pharma Inc. (NASDAQ:CERU), Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - The Voice Registrar
07/21/16 06:51 AMInsiders Increasing Positions in: Cerulean Pharma Inc. (NASDAQ:CERU) - Press Telegraph
07/20/16 04:14 PMCerulean Pharma Inc. (NASDAQ:CERU): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/20/16 04:14 PMCerulean Pharma Inc Stock Technicals at Critical Inflection Point - CML News
07/20/16 04:14 PMShares Jumping Higher in Session: Cerulean Pharma Inc. (NASDAQ:CERU) - TGP
07/20/16 11:11 AMHeightened Volatility Spotted on Shares of: Cerulean Pharma Inc. (NASDAQ:CERU) - Engelwood Daily
07/20/16 11:11 AMTrading Action Review: Watching Unusual Volume on Cerulean Pharma Inc. (NASDAQ:CERU) - Engelwood Daily
07/20/16 11:11 AMBiotech Stocks To Put On Your Watch List: Cerulean Pharma Inc. (NASDAQ:CERU), Opko Health, Inc. (NASDAQ:OPK) - The Voice Registrar
07/19/16 05:56 PMWhy Did Cerulean Pharmaceuticals (CERU) Surge 30% Today? -
07/19/16 03:12 PMDow Jones Industrial Average Winning Streak in Jeopardy
07/19/16 03:12 PMCerulean Pharma Worth a Look: Stock Gains 9.1%
07/19/16 11:45 AMWhy These Stocks Are Gaining Ground on Tuesday? -
07/19/16 09:31 AMCerulean Pharma : Receives FDA Fast Track Designation for CRLX101 for the Treatment of Platinum-Resistant Ovarian Cancer
07/19/16 06:30 AM7:30 am Cerulean Pharma announces that the FDA granted Fast Track designation for CRLX101, in combination with paclitaxel, for the treatment of platinum-resistant ovarian carcinoma, fallopian tube or primary peritoneal cancer -
07/19/16 06:30 AMCerulean Receives FDA Fast Track Designation for CRLX101 for the Treatment of Platinum-Resistant Ovarian Cancer - [Business Wire] - Cerulean Pharma Inc. , a clinical-stage company developing nanoparticle-drug conjugates , today announced that the U.S. Food and Drug Administration granted Fast Track designation for Cerulean’s lead nanoparticle-drug conjugate, CRLX101, in combination with paclitaxel, for the treatment of platinum-resistant ovarian carcinoma, fallopian tube or primary peritoneal cancer.
07/18/16 08:10 AMCerulean Pharma Incorporated (NASDAQ:CERU) Short Interest Decreased By 13.2% - Press Telegraph
07/18/16 08:10 AMCerulean Pharma Inc. (NASDAQ:CERU) Wall Street Analyst Recommendation Outlook - TGP
07/14/16 08:37 PMCerulean Pharma Inc. (NASDAQ:CERU) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/14/16 08:37 PMCerulean Pharma Inc. (NASDAQ:CERU) 2016 Q1 Sentiment Report - Consumer Eagle
07/13/16 09:37 AMBroker Outlook For Cerulean Pharma Inc. (CERU) - Fiscal Standard
07/11/16 03:06 PMStock Volatility Focus for: Cerulean Pharma Inc. (NASDAQ:CERU) - Engelwood Daily
07/11/16 07:59 AMWall Street Ratings and Target Price Views on Cerulean Pharma Inc. (NASDAQ:CERU) - Telanagana Press
07/10/16 03:03 PMNext Weeks Broker Price Targets For Cerulean Pharma Inc. (CERU) - Fiscal Standard
07/10/16 07:49 AMCerulean Pharma Incorporated (NASDAQ:CERU) Shorts Decreased by 13.2% After Short Covering - Engelwood Daily
06/30/16 08:36 PMWatching Stock Volatility for: Cerulean Pharma Inc. (NASDAQ:CERU) - Engelwood Daily
06/30/16 08:36 PMCerulean Pharma Incorporated (NASDAQ:CERU) Shorted Shares Decreased By 13.2% - Engelwood Daily
06/30/16 08:36 PMCerulean Pharma Inc. (CERU) Current Analyst Ratings - Fiscal Standard
06/28/16 02:29 PMCheck on Share Volatility: Cerulean Pharma Inc. (NASDAQ:CERU) - Engelwood Daily
06/28/16 02:29 PMCovering the Bases on Cerulean Pharma Inc. (NASDAQ:CERU): Where is the Stock Going? - Press Telegraph
06/27/16 03:17 PMCERULEAN PHARMA INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/27/16 07:45 AMCerulean Pharma Inc. (CERU) Broker Price Targets For The Coming Week - Fiscal Standard
06/23/16 04:38 PMNew Broker Ratings For Cerulean Pharma Inc. (CERU) - FTSE News
06/23/16 10:55 AMCerulean Pharma : Announces First Patient Dosed in Phase 2a Expansion Stage Evaluating CRLX301 in Patients with Advanced Solid Tumors
06/23/16 06:19 AMCerulean Announces First Patient Dosed in Phase 2a Expansion Stage Evaluating CRLX301 in Patients with Advanced Solid Tumors - [at noodls] - WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that the first patient has been dosed in the ...
06/22/16 08:29 AMCerulean Announces Publication in Cancer Research - [at noodls] - Paper Highlights Preclinical Proof of Concept of CRLX101 in Combination with Avastin (bevacizumab) in Models of Metastatic Triple-Negative Breast Cancer WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma ...
06/19/16 03:01 PMCerulean Pharma Inc. (CERU) Analyst Price Targets For The Coming Week - Fiscal Standard
06/15/16 03:14 PMBiotechnology Volatile Stocks: ImmunoGen, Inc. (NASDAQ:IMGN), Cerulean Pharma Inc. (NASDAQ:CERU), Eleven ... - KC Register
06/14/16 06:09 AMCerulean to Present at JMP Securities Life Sciences Conference - [at noodls] - WALTHAM, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ: CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that Christopher D. T. Guiffre, President ...
06/10/16 04:03 PMCerulean Pharma, Inc. :CERU-US: Earnings Analysis: Q1, 2016 By the Numbers : June 10, 2016 -
06/09/16 06:19 AMCerulean Announces Manuscript Published in Annals of Oncology - [at noodls] - Data from 22 Evaluable Metastatic Renal Cell Carcinoma Patients Treated with CRLX101 in Combination with Avastin® in Phase 1b/2 Investigator-Sponsored Trial Led by University of Pennsylvania WALTHAM, Mass.--(BUSINESS ...

Social

About Cerulean Pharma

Cerulean Pharma logoCerulean Pharma Inc. is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform utilizes nanoparticle-drug conjugates (NDCs), which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads. Its NDC platform is designed to create NDCs that accumulate high concentrations of active drug in tumor cells, without exposure to healthy tissue. Its platform is applicable to a range of payloads. It has created NDCs with a range of small molecule payloads, including Jevtana (cabazitaxel), gemcitabine, methotrexate and Xeljanz (tofacitinib). The Company's product pipeline consists of CRLX101 and CRLX301. Its CRLX101 is a tumor targeted NDC. Its CRLX301 has docetaxel as its anti-cancer payload. CRLX101 has a camptothecin payload, which is a topoisomerase 1 (topo 1) inhibitor. CRLX301 is designed to concentrate docetaxel in tumor cells and spare healthy tissue.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CERU
  • CUSIP:
Key Metrics:
  • Previous Close: $2.95
  • 50 Day Moving Average: $2.28
  • 200 Day Moving Average: $2.50
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $74.70M
  • Beta: 1.57
  • Current Year EPS Consensus Estimate: $-1.80 EPS
  • Next Year EPS Consensus Estimate: $-1.97 EPS
Additional Links:
Cerulean Pharma (NASDAQ:CERU) Chart for Monday, July, 25, 2016